Expression and Prognostic Relevance of MAGE-A3 and MAGE-C2 in Non-small Cell Lung Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2017 Apr 30

PMID 28454298

Citations 23

Authors

Xinfeng Chen

Liping Wang

Jinyan Liu

Lan Huang

Li Yang

Qun Gao

Xiaojuan Shi

Jieyao Li

Feng Li

Zhen Zhang

Song Zhao

Bin Zhang

Pierre van der Bruggen

Yi Zhang

Affiliations

Soon will be listed here.

Abstract

Melanoma-associated antigen (MAGE)-A3 and MAGE-C2 are antigens encoded by cancer-germline genes, and have been recognized as potential prognostic biomarkers and attractive targets for immunotherapy in multiple types of cancer. The present study aimed to analyze the clinicopathological significance of MAGE-A3/C2 expression in non-small cell lung cancer (NSCLC). The association between MAGE-A3/C2 mRNA and protein expression, and the pathological characteristics and overall survival of patients with NSCLC was analyzed. In addition, the functional role of MAGE-A3 in human NSCLC cell line A549 was examined . MAGE-A3/C2 mRNA expression was identified in 73% (151/206) and 53% (109/206) of patients with NSCLC, respectively. MAGE-A3/C2 protein expression was identified in 58% (44/76) and 53% (40/76) of NSCLC cases, respectively. MAGE-A3 mRNA expression was observed to be associated with smoking history, disease stage and lymph node metastasis. However, no association was identified between MAGE-C2 mRNA expression and the clinicopathological characteristics of patients with NSCLC. MAGE-A3/C2-positive patients had a poorer survival rate compared with MAGE-A3/C2-negative patients. Multivariate analysis identified that MAGE-A3 expression may serve as an independent marker of poor prognosis in patients with NSCLC. Downregulation of MAGE-A3 mRNA expression in A549 cells resulted in lower migration and colony formation rates, and a higher amount of epithelial marker and lower amount of mesenchymal marker expression compared with the control group. These results indicate that MAGE-A3 serves a role in NSCLC cell metastasis through the induction of epithelial-mesenchymal transition. In conclusion, MAGE-A3 may serve as a diagnostic and prognostic biomarker for patients with NSCLC, due to its association with tumor progression and poor clinical outcome.

Citing Articles

Increased Family Gene Expression Levels as a Biomarker of Colon Cancer Through the Demethylation Mechanism.

Almutairi M, Alsoraie W, Alrubie T, Alkhaldi A, Alhajri N, Alaujan M Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598359 PMC: 11597369. DOI: 10.3390/ph17111447.

Expression pattern analysis of the family genes in breast cancer patients and hypomethylation activation in the MCF-7 cells.

Almatrafi A, Alamery S, Almutairi M Heliyon. 2024; 10(14):e34506.

PMID: 39082035 PMC: 11284374. DOI: 10.1016/j.heliyon.2024.e34506.

Reconceiving Perineural Invasion in Cutaneous Squamous Cell Carcinoma: From Biological to Histopathological Assessment.

Nozzoli F, Nassini R, De Logu F, Catalano M, Roviello G, Massi D Pathobiology. 2024; 91(6):442-454.

PMID: 39047688 PMC: 11614312. DOI: 10.1159/000539484.

Cancer testis antigen MAGEA3 in serum and serum-derived exosomes serves as a promising biomarker in lung adenocarcinoma.

Gan Y, Kang Y, Zhong R, You J, Chen J, Li L Sci Rep. 2024; 14(1):7573.

PMID: 38555374 PMC: 10981702. DOI: 10.1038/s41598-024-58003-z.

DUB3 is a MAGEA3 deubiquitinase and a potential therapeutic target in hepatocellular carcinoma.

Chen Y, Gao F, He Y, Liu M, Quan Y, Zhang P iScience. 2024; 27(3):109181.

PMID: 38414853 PMC: 10897913. DOI: 10.1016/j.isci.2024.109181.

References

Yang F, Zhou X, Miao X, Zhang T, Hang X, Tie R . MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis. Breast Cancer Res Treat. 2014; 145(1):23-32. PMC: 3984411. DOI: 10.1007/s10549-014-2915-9. View

Rapoport A, Stadtmauer E, Binder-Scholl G, Goloubeva O, Vogl D, Lacey S . NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015; 21(8):914-921. PMC: 4529359. DOI: 10.1038/nm.3910. View

Fourcade J, Sun Z, Pagliano O, Chauvin J, Sander C, Janjic B . PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines. Cancer Res. 2013; 74(4):1045-55. PMC: 3952491. DOI: 10.1158/0008-5472.CAN-13-2908. View

van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B . A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991; 254(5038):1643-7. DOI: 10.1126/science.1840703. View

Tajima K, Obata Y, Tamaki H, Yoshida M, Chen Y, Scanlan M . Expression of cancer/testis (CT) antigens in lung cancer. Lung Cancer. 2003; 42(1):23-33. DOI: 10.1016/s0169-5002(03)00244-7. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Rao M, Chinnasamy N, Hong J, Zhang Y, Zhang M, Xi S . Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer. Cancer Res. 2011; 71(12):4192-204. PMC: 3116976. DOI: 10.1158/0008-5472.CAN-10-2442. View

Eikawa S, Kakimi K, Isobe M, Kuzushima K, Luescher I, Ohue Y . Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide. Int J Cancer. 2012; 132(2):345-54. DOI: 10.1002/ijc.27682. View

Olarte I, Martinez A, Ramos-Penafiel C, Castellanos-Sinco H, Zamora J, Collazo-Jaloma J . MAGE-A3 expression is an adverse prognostic factor in diffuse large B-cell lymphoma. Hematology. 2011; 16(6):368-72. DOI: 10.1179/102453311X13085644680384. View

10.

Pabst C, Zustin J, Jacobsen F, Luetkens T, Kroger N, Schilling G . Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma. Exp Mol Pathol. 2010; 89(2):175-81. DOI: 10.1016/j.yexmp.2010.06.011. View

11.

Laban S, Atanackovic D, Luetkens T, Knecht R, Busch C, Freytag M . Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer. Int J Cancer. 2014; 135(5):1142-52. DOI: 10.1002/ijc.28752. View

12.

Vaughan H, Svobodova S, MacGregor D, Sturrock S, Jungbluth A, Browning J . Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res. 2004; 10(24):8396-404. DOI: 10.1158/1078-0432.CCR-04-0809. View

13.

Yoshida N, Abe H, Ohkuri T, Wakita D, Sato M, Noguchi D . Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int J Oncol. 2006; 28(5):1089-98. View

14.

Detterbeck F, Postmus P, Tanoue L . The stage classification of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl):e191S-e210S. DOI: 10.1378/chest.12-2354. View

15.

Sienel W, Varwerk C, Linder A, Kaiser D, Teschner M, Delire M . Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg. 2003; 25(1):131-4. DOI: 10.1016/j.ejcts.2003.09.015. View

16.

Chen X, Wang L, Yue D, Liu J, Huang L, Yang L . Correlation between the high expression levels of cancer-germline genes with clinical characteristics in esophageal squamous cell carcinoma. Histol Histopathol. 2016; 32(8):793-803. DOI: 10.14670/HH-11-847. View

17.

Bhutani M, Kumar Pathak A, Tang H, Fan Y, Liu D, Lee J . Frequent expression of MAGE1 tumor antigens in bronchial epithelium of smokers without lung cancer. Exp Ther Med. 2012; 2(1):137-142. PMC: 3440643. DOI: 10.3892/etm.2010.176. View

18.

Grah J, Samija M, Juretic A, Sarcevic B, Sobat H . Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features. Coll Antropol. 2008; 32(3):731-6. View

19.

Hofmann O, Caballero O, Stevenson B, Chen Y, Cohen T, Chua R . Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A. 2008; 105(51):20422-7. PMC: 2603434. DOI: 10.1073/pnas.0810777105. View

20.

Andrade V, Vettore A, Silva M, Felix R, Almeida M, de Carvalho F . Frequency and prognostic relevance of cancer testis antigen 45 expression in multiple myeloma. Exp Hematol. 2009; 37(4):446-9. DOI: 10.1016/j.exphem.2008.12.003. View